The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 9, 2007, Pages 979-987

  Burke, Thomas A ^a,d   Sturkenboom, Mirian C ^b   Ohman Strikckland, Pamela A ^a   Wentworth, Charles E ^c   Rhoads, George G ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Analytic Consulting Solutions   (United States)

^d NONE   (United States)

Author keywords

Antihypertensive drugs; Cohort; Diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FACTUAL DATABASE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THIAZIDES; TREATMENT OUTCOME;

EID: 34548744112     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1444     Document Type: Article

References (34)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139(2 Pt 1): 272-281.
3. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25: 40-43.
4. United Kingdom Prospective Diabetes Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33). Lancet 1998; 352(9131): 837-853.
5. DeFronzo RA, Ferranni E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
6. Uehara M, Kishikawa H, Isami S, et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: BK may improve insulin resistance in dogs and humans. Diabetologia 1994; 37: 300-307.
7. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 1998; 46: 467-471.
8. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of antihypertensive treatment with nifedipine or furosemide: a double blind cross-over study. J Hum Hypertens 1995; 9:37-41.
9. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med 1997; 126: 955-959.
10. Gudbjorndottir S, Fowelin J, Elam M, et al. The effect of metoprolol on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects. Eur J Clin Invest 1997; 17: 29-35.
11. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997.
12. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 2003; 41: 431-436.
13. Niklason A, Hedner T, Niskanen L, Lanke J. Development of diabetes is retarded by ACE inhibition in hypertensive patients - a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004; 22: 645-652.
14. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
15. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.
16. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999; 354: 1751-1756.
17. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the nordic diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
18. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
19. National Guideline Research and Development Unit. Essential hypertension: managing adult patients in primary care: final consultation draft. University of Newcastle Upon Tyne, January 31, 2004.
20. EPIC. EPICGPRD: A Guide for Researchers. EPIC: London, 2003.
21. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689.
22. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000; 342: 905-912.
23. Padwal R, Mamdani M, Alter DA, et al. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004; 27: 2458-2463.
24. Yusuf S, Gerstein H, Hoogweerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
25. Gurwitz JH, Field TS, Glynn RJ, et al. Risk factors for non-insulin dependent diabetes mellitus requiring treatment in the elderly. J Am Geriatr Soc 1994; 42: 1235-1240.
26. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369(9557): 201-207.
27. Lam HC, Lee JK, Chiang HT, Chuang MJ, Wang MC. Is captopril-induced improvement of insulin sensitivity mediated via endothelin? J Cardiovasc Pharmacol 1998; 31 (Suppl 1): S496-S500.
28. Ferri C, Laurenti O, Bellini C, et al. Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients: influence of ACE inhibition. AJH 1995; 8: 40-47.
29. Tomiyama H, Kushiro T, Abeta H, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23: 450-455.
30. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999; 46: R332-R336.
31. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. New Engl J Med 2006; 355: 1551-1562.
32. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
33. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
34. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.